摘要
[目的]探讨欣胃颗粒对胃癌前病变患者Bcl-2、C-myc、P53及P16蛋白表达的影响。[方法]符合纳入标准的60例气阴两虚、挟瘀挟毒型胃癌前病变患者作为治疗前组,再将其随机分为治疗1组30例,治疗2组30例,治疗1组给予欣胃颗粒,治疗2组给予胃复春片,疗程均为12周,另选在此期间就诊的慢性浅表性胃炎患者10例作为正常组。观察4组患者Bcl-2、C-myc、P53及P16的含量变化。[结果]与正常组比较,胃癌前病变的发生与Bcl-2、C-myc的含量上升及P53、P16的含量下降有关,与治疗前组比较,治疗1组、2组差异均有统计学意义(P<0.05),说明治疗组能够下调Bcl-2、C-myc和上调P53、P16蛋白水平,且治疗1组优于治疗2组(P<0.05)。[结论]欣胃颗粒能通过下调Bcl-2、C-myc和上调P53、P16从而有效缓解胃癌前病变患者的临床症状,延缓病情进展,值得临床推广应用。
[Objective]To study the effect of Xinwei granules on Bcl-2,C-myc,P53 and P16 in patients with precancerous lesions of gastric cancer.[Methods]60patients with Qi-Yin deficiency and stasis toxin type PLGC were served as the group of before treatment,and then they were randomizedly divided into treatment group 1 with 30 patients and treatment 2with 30 patients,the patients in treatment group 1 received Xinwei granules and the patients in treatment group 2 took Weifuchun tablets,and the courses of treatment fot both groups were 12 weeks.In addition,10 patients with chronic superficial gastritis were served as the normal group.The content changes of Bcl-2,C-myc,P53 and P16 in 4groups were observed.[Results]By comparing with the normal group,we can find that the occurrence of PLGC is related to the increase of Bcl-2,C-myc and the decrease of P53,P16 .By comparing with the group of before treatment,it iseasy to see that the difference between treatment group 1and 2is statistically significant（P〈0.05）,it shows that the treatment group could decrease the level of Bcl-2,C-myc protein and increase the level of P53,P16 protein,and the effect of treatment group 1 is better than treatment group 2（P〈0.05）.[Conclusion]Xinwei granules could decrease the level of Bcl-2,Cmyc and increase the level of P53,P16 ,and it could effectively relieve clinical symptoms,check the progress of disease,so it is worth to be popularized in clinical application.
出处
《中国中西医结合消化杂志》
CAS
2017年第6期419-421,426,共4页
Chinese Journal of Integrated Traditional and Western Medicine on Digestion
基金
国家教育部春晖计划项目(No:Z2010031)
黑龙江省博士后基金(No:LBH-Z12266)
